key: cord-0919092-u6e7g7sn
authors: Hermans, Cedric; Lambert, Catherine
title: Impact of the COVID‐19 pandemic on therapeutic choices in thrombosis‐hemostasis
date: 2020-05-11
journal: J Thromb Haemost
DOI: 10.1111/jth.14845
sha: 649ebcb47bf5ba134662f1ac501788b376d8c9ed
doc_id: 919092
cord_uid: u6e7g7sn

Major therapeutic developments have been achieved in the field of thrombotic and hemorrhagic diseases over the last decade. These include the development and validation of four direct oral anticoagulants (DOACs) indicated for numerous thrombotic disorders, both arterial and venous [1]. It also involves new haemostatic agents for hemophilia patients, in particular Factor VIII (FVIII) and Factor IX (FIX) concentrates with extended half-life (EHL) [2;3] and a bispecific antibody mimicking the action of FVIII (Emicizumab) [4;5].

Major therapeutic developments have been achieved in the field of thrombotic and hemorrhagic diseases over the last decade. These include the development and validation of four direct oral anticoagulants (DOACs) indicated for numerous thrombotic disorders, both arterial and venous. 1 Developments also involve new hemostatic agents for hemophilia patients, in particular factor VIII (FVIII) and factor IX (FIX) concentrates with extended half-life (EHL) 2,3 and a bispecific antibody mimicking the action of FVIII (emicizumab). 4, 5 No one can dispute the major benefits of these widely adopted drugs, which have fundamentally changed the management of many For emicizumab, too, the benefits are numerous: avoidance of intravenous injections, which is important for patients unable to perform self-infusions; infrequent subcutaneous injections; stable effect providing very good and prolonged protection against bleeding episodes, including patients with inhibitors against FVIII.

The newer direct oral anticoagulants: a practical guide

Benefits and limitations of extended plasma halflife factor VIII products in hemophilia A

Extended half-life recombinant products in haemophilia clinical practice -Expectations, opportunities and challenges

Emicizumab for the treatment of haemophilia A: a narrative review

Emicizumab for the prevention of bleeds in hemophilia A

Comparison of the non-VKA oral anticoagulants apixaban, dabigatran, and rivaroxaban in the extended treatment and prevention of venous thromboembolism: systematic review and network meta-analysis

Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis

Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis